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Items for this week’s Epi Update include: 
• Candida auris now temporarily reportable in Iowa  
• Vaping-related illnesses reported among Iowa young adults 
• HPV vaccination recommendations for adults 
• In the news: Africa begins countdown to being polio free as Nigeria marks 3 years 
without disease 
• In the news: The world before vaccines is a world we can’t afford to forget 
• In the news: Cases of vape-related lung damage rise to at least 153 
• Infographic: Protect your preteen patients today with HPV vaccine 
 
Candida auris now temporarily reportable in Iowa  
C. auris is an emerging fungus that presents a serious global health threat. CDC recommends 
that all Candida isolates obtained from normally sterile sites (e.g., bloodstream, cerebrospinal 
fluid) be identified to the species level so initial treatment can be administered based on 
typical, species-specific susceptibility patterns. Identification of C. auris in a non-sterile body 
site is also significant because it can represent wider colonization, which poses a risk for 
transmission and infection control precautions.  
 
C. auris can be misidentified as other types of fungi unless specialized laboratory technology is 
used. C. auris may be the true organism if the following results are given by your identification 
system: 
• Candida auris 
• Candida famata 
• Candida haemulonii 
• Candida sake 
• Rhodotorula glutinis 
• Saccharomyces cerevisiae 
• Candida spp. (isolates where the species is attempted and results are inconclusive) 
 
All laboratories should submit isolates from any site that include the above species to SHL for 
further characterization.  
 
For questions about C. auris reporting, please contact the CADE HAI/AR team at  
800-362-2736. 
 
Vaping-related illnesses reported among Iowa young adults 
Several states have recently reported cases of severe respiratory illness among teenagers and 
young adults with a history of vaping. Reported symptoms include cough, fatigue, dizziness, 
headache, vomiting and diarrhea, chest pain, and worsening difficulty breathing, sometimes 
requiring intensive care. A variety of vaping products associated with the illnesses have been 
reported. 
 
 
Four cases of respiratory illness in young adults with a history of vaping have been reported to 
IDPH. The patients are young adults (early to mid-20s) from across Iowa who report vaping 
prior to becoming ill. These cases are still being investigated, but three patients have reported 
use of vaping products that contain THC. 
 
Youth should be discouraged from using vaping and e-cigarette products of any kind as the 
long-term health impacts for youth using these products are unknown. Patients with a history 
of vaping who are experiencing breathing problems should seek medical care. Health care 
providers should ask patients with respiratory illness about the use of vaping and e-cigarette 
products.  
 
Health care providers are asked to report severe respiratory illness in patients with a history of 
vaping or e-cigarette use to IDPH at 1-800-362-2736. 
 
For more information, visit  
www.cdc.gov/media/releases/2019/s0821-cdc-fda-states-e-cigarettes.html.  
 
HPV vaccination recommendations for adults 
The Advisory Committee on Immunization Practices (ACIP) has released two new 
recommendations for HPV vaccination. First, catch-up vaccination is now recommended for all 
persons through age 26. This change harmonizes catch-up recommendations for both males 
and females. Second, shared clinical decision making regarding HPV vaccination is 
recommended for some adults aged 27-45. Catch-up vaccination is not recommended for all 
adults in this age group. Instead, clinicians should consider discussing HPV vaccination with 
persons who are most likely to benefit. HPV vaccination does not need to be discussed with 
most adults older than 26. 
 
Adolescents remain the most important focus of HPV vaccination and recommendations for 
this age group have not changed. Routine HPV vaccination continues to be recommended at 
age 11-12, and is most effective when given before exposure to HPV.  
 
For more information about the new HPV vaccination recommendations for adults, visit 
www.cdc.gov/mmwr/volumes/68/wr/mm6832a3.htm.  
 
In the news: Africa begins countdown to being polio free as Nigeria marks 3 years 
without disease 
www.cnn.com/2019/08/21/health/africa-countdown-polio-eradication/index.html  
 
In the news: The world before vaccines is a world we can’t afford to forget 
www.nationalgeographic.com/culture/2019/08/cannot-forget-world-before-vaccines/  
 
In the news: Cases of vape-related lung damage rise to at least 153 
www.nbcnews.com/health/kids-health/cases-mysterious-vaping-related-illnesses-rise-least-
127-n1044281  
 
 
 
 
 
Infographic: Protect your preteen patients today with HPV vaccine 
 
 
To view in full size, visit  
www.cdc.gov/hpv/hcp/hpv-important/more-than-screening-infographic.html.  
 
Have a healthy and happy week! 
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